Opportunities and challenges for anti-CD47 antibodies in hematological malignancies

Front Immunol. 2024 Feb 23:15:1348852. doi: 10.3389/fimmu.2024.1348852. eCollection 2024.

Abstract

CD47 is a cell-surface ligand that is overexpressed in various malignancies and that binds to SIRPα on macrophages to promote tumor cell evasion of phagocytosis. Blocking the CD47-SIRPα axis can increase the phagocytosis of macrophages to exert antitumor effects. CD47-based immunotherapy is a current research focus. The combination of anti-CD47 antibodies with other drugs has shown encouraging response rates in patients with hematological tumors, but side effects also occur. Bispecific antibodies and SIRPα/Fc fusion proteins appear to balance the efficacy and safety of treatment. We review the latest clinical research advances and discuss the opportunities and challenges associated with CD47-based immunotherapy for hematological malignancies.

Keywords: anti-CD47 antibody; cd47; hematological malignancies; immunotherapy; magrolimab.

Publication types

  • Review
  • Research Support, Non-U.S. Gov't

MeSH terms

  • CD47 Antigen / metabolism
  • Hematologic Neoplasms* / drug therapy
  • Hematologic Neoplasms* / metabolism
  • Humans
  • Macrophages
  • Neoplasms* / therapy
  • Phagocytosis

Substances

  • CD47 Antigen
  • CD47 protein, human

Grants and funding

The author(s) declare financial support was received for the research, authorship, and/or publication of this article. This work was supported by the Zhejiang Provincial Natural Science Foundation of China (LY20H080002), and the Medical Health Science and Technology Project of Zhejiang Provincial Health Commission (2019KY452).